Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

A Prospective, Single-Arm Study to Evaluate the Safety and Efficacy of an Autologous Blood Clot Product in the Treatment of Anal Fistula

Ram E., Zager Y., Carter D., Saukhat O., Anteby R., Nachmany I.

Prospective Study with a reported sample of 33 on Autoimmune Research, published in Dis Colon Rectum (2024) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Dis Colon Rectum (2024)
Reported sample size
33
Source database
Europe PMC
PMID
38149981
PMCID
PMC10901226
DOI
10.1097/dcr.0000000000003190
Citations
4

Abstract (original English)

Background Surgical treatment of complex perianal fistula is technically challenging, associated with risk of failure, and may require multiple procedures. In recent years, several biologic agents have been developed for permanently eradicating anal fistulous disease with variable success. In this study, the treatment is an autologous whole-blood product created from the patients' blood. It forms a provisional matrix that was found to be safe and effective in healing acute and chronic cutaneous wounds. Objective The study aimed to assess the efficacy and safety of an autologous blood clot product as a treatment for transsphincteric perianal fistulas. Design A prospective single-arm study. Settings A single tertiary medical center. Patients Patients with simple or complex transsphincteric fistulas confirmed by MRI were included in the study. Cause was either cryptoglandular or Crohn's disease related (in the absence of active luminal bowel disease). Intervention The outpatient procedure was performed under general anesthesia and consisted of: 1) physical debridement and cleansing of the fistula tract; 2) suture closure of the internal opening; and 3) instillation of the autologous blood clot product into the entire tract. Main outcome measures Safety and efficacy at 6- and 12-months after surgery. Results Fifty-three patients (77% men) with a median age of 42 (20-72) years were

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansRectal FistulaCrohn DiseaseAnus DiseasesTreatment OutcomeProspective StudiesPilot ProjectsAdultAgedMiddle Aged

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research